Endothelial cell KIT expression in human tumours

Journal of Pathology

Volumn 211, Issue 4, 2007, Pages 481-488

  Sihto, Harri ^a   Tynninen, O ^b   Butzow R ^b   Saarialho Kere, U ^b   Joensuu, H ^a,b  

^a Laboratory of Molecular Oncology   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

c KIT receptor; Endothelial cells; Gliobastoma; Hypoxia inducible factor 1, alpha subunit; Imatinib; Mammalian target of rapamycin (mTOR); Tyrosine kinase receptors

Indexed keywords

HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN KINASE B; SODIUM; STEM CELL FACTOR RECEPTOR;

ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; COLON CARCINOMA; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADENOCARCINOMA; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; NECROSIS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER; RNA, NEOPLASM; STEM CELL FACTOR;

EID: 33847414570     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2125     Document Type: Article

References (30)

1. Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelia] cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virrhows Arch 1994;424:135-141.
2. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.
3. Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, et al. Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer 2004;90:2397-2401.
4. Looijenga LH, de Leeuw H, van Oorschot M, van Gurp RJ, Stoop H, Gillis AJ, et al. Stem cell factor receptor (c-Kit) codon 816 mutations predict development of bilateral testicular tumors. Cancer Res 2003;63:7674-7678.
5. Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, et al. KIT and platelet-derived-growth factor receptor alpha tyrosine kinase mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57.
6. Hornick JL, Fletcher CD. Inummohistochemical staining for KIT (CD 117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-193.
7. Joensuu H, Dimitrijevic S, Silberman S, Roberts PJ, Demetri GD. Management of gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-664.
8. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005;207:224-231.
9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
10. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.
11. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997;32:253-265.
12. Parikka M, Kainulainen T, Tasanen K, Bruckner-Tuderman L, Salo T. Altered expression of collagen XVII in ameloblastomas and basal cell carcinomas. J Oral Pathol 2001;30:589-595.
13. Reifenberger G, Collins VP. Pathology and molecular genetics of astrocytic gliomas. J Mol Med 2004;82:656-670.
14. Gaudin PB, Rosai J. Florid vascular proliferation associated with neural and neuroendocrine neoplasms. A diagnostic clue and potential pitfall. Am J Surg Pathol 1995;19:642-652.
15. Matsui J, Wakabayashi T, Asada M, Yoshimatsu K, Okada M. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem 2004;279:18600-18607.
16. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biol 2000;2:423-427.
17. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-25741.
18. Jin K, Mao XO, Sun Y, Xie L, Greenberg DA. Stem cell factor stimulates neurogenesis in vitro and in vivo. J Clin Invest 2002;110:311-319.
19. Jögi A, Ora I, Nilsson H, Lindeheim Å, Makino Y, Poellinger L, et al. Hypoxia alters gene expression in human neuroblastoma cells towards an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A 2002;99:7021-7026.
20. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia- inducible factor-1α activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 2006;5:1415 -1422.
21. Erlandsson A, Larsson J, Forsberg-Nilsson K. Stem cell factor is a chemoattractant and a survival factor for CNS stem cells. Exp Cell Res 2004;301:201-210.
22. Berdel WE, de Vos S, Maurer J, Oberberg D, von Marschall Z, Schroeder JK, et al. Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. Cancer Res 1992;52:3498-3502.
23. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000;50:121-127.
24. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-443.
25. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-123.
26. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
27. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005;10:1702-1708.
28. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23:9353-9368.
29. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, et al. Targeting platelet-derived growth factor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006;98:787-793.
30. Arismendi-Morillo G, Castellano A. Tumoral micro-blood vessels and vascular microenvironment in human astrocytic tumors. A transmission electron microscopy study. J Neurooncol 2005;73:211-217.